NLRP3 inflammasome and IL-1β pathway in type 2 diabetes and atherosclerosis: Friend or foe?

Pharmacol Res. 2021 Nov:173:105885. doi: 10.1016/j.phrs.2021.105885. Epub 2021 Sep 16.

Abstract

Type 2 diabetes and atherosclerosis have gradually garnered great attention as inflammatory diseases. Previously, the fact that Interleukin-1β (IL-1β) accelerates the development of type 2 diabetes and atherosclerosis has been proved in animal experiments and clinical trials. However, the continued studies found that the effect of IL-1β on type 2 diabetes and atherosclerosis is much more complicated than the negative impact. Nucleotide-binding oligomerization domain and leucine-rich repeat pyrin 3 domain (NLRP3) inflammasome, whose activation and assembly significantly affect the release of IL-1β, is a crucial effector activated by a variety of metabolites. The diversity of NLRP3 activation mode is one of the fundamental reasons for the intricate effects on the progression of type 2 diabetes and atherosclerosis, providing many new insights for us to intervene in metabolic diseases. This review focuses on how NLRP3 inflammasome affects the progression of type 2 diabetes and atherosclerosis and what opportunities and challenges it can bring us.

Keywords: Anakinra (PubChem CID: 139595263); Atherosclerosis; CY-09 (PubChem CID: 134812841); IL-1β; Inflammasome; Insulin resistance; MCC950 (PubChem CID: 9910393); NLRP3; Oridonin (PubChem CID: 5321010); Tranilast (PubChem CID: 5282230); Type 2 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Atherosclerosis / immunology*
  • Diabetes Mellitus, Type 2 / immunology*
  • Humans
  • Inflammasomes / immunology*
  • Interleukin-1beta / immunology*
  • NLR Family, Pyrin Domain-Containing 3 Protein / immunology*
  • Signal Transduction

Substances

  • Inflammasomes
  • Interleukin-1beta
  • NLR Family, Pyrin Domain-Containing 3 Protein